Summary At a median time of 20 months following high dose melphalan for myeloma, 29 patients relapsed and were treated with induction chemotherapy to maximum response followed by a second course of high dose melphalan. The majority (90%) of patients received 200 mg m2 with an autologous bone marrow transplant. Sixteen (55%) patients achieved complete remission and 11 (38%) a partial response. The median duration of remission was 17 (4-42) months. The median survival has not been reached, with 50% of patients alive at 58 + months after presentation. The period of neutropenia was similar during both first and second high dose procedures, but the duration of thrombocytopenia was longer in patients receiving melphalan for a second time (median 22 (16-56) 
The use of high dose melphalan (HDM) as a single treatment in patients with meyloma is associated with a high response rate (McElwain & Powles, 1983; Selby et al., 1987) . Complete remission, defined by undetectable myeloma protein on immunoelectrophoresis and normal bone marrow morphology (Gore et al., 1989 ) occurs in about 30% of patients with a further 50% achieving a partial response (Selby et al., 1987) . The median duration of remission in responding patients is 19 months with nearly all patients eventually relapsing. In patients who have failed previous chemotherapy with alkylating agents (usually low dose melphalan) the response rate to HDM remains high at 66% but the duration of remission is short, with a median of only 6 months and all patients relapsing within a year (Selby et al., 1987) . The toxicity of this approach is predictable with a median period of myelosuppression and thrombocytopenia of 28 and 24 days in previously untreated patients, and 42 and 37 days in previously treated patients respectively (McElwain et al., 1989) .
The incorporation of an induction regimen to maximum response prior to HDM has been used to try to improve the complete remission rate and duration of remission. This regimen consists of a 4 day continuous infusion of vincristine, doxorubicin and methylprednisolone (VAMP) given every 3 weeks, and has been used successfully in previously treated and untreated patients (Forgeson et al., 1988; Gore et al., 1989) to reduce tumour burden and the degree of marrow infiltration. In those patients in whom the marrow infiltration falls to less than 30% a higher dose of melphalan can then be given together with an autologous bone marrow transplant (ABMT), and this reduces the period of bone marrow suppression (McElwain et al., 1989) .
Since all patients eventually relapse following HDM further treatment is always necessary. It is the practice in our unit to treat relapsed patients with induction chemotherapy to maximum response. Recently weekly cyclophosphoamide has been added to VAMP in the hope of improving the efficacy of the regimen. Bell et al. (1988) (Kaplan & Meier, 1987) and the differences assessed using the log-rank test (Peto et al., 1977 (Gore et al., 1989) ; for those patients who received C.R. following the second HDM the duration of response is dated from when this occurred.
Patients were reviewed 3 monthly in the clinic. Relapse was defined as reappearance of a paraprotein/Bence-Jones proteinuria and/or bone marrow infiltration with >5% myeloma cells.
Results
Response to induction chemotherapy and HDM The complete remission rate to VAMP or cVAMP was 18% (five of 28) with an overall response rate of 54% (Table II) .
A further 12 patients converted to complete remission following HDM; four of these patients had not responded to induction chemotherapy. The overall complete remission rate was therefore 55% (16/29 Figure 2 . Grade 3/4 stomatitis and diarrhoea occurred in two (11%) and one (6%) patients following the first high dose procedure and six (33%) and five (28%) following the second high dose procedure respectively. The majority of patients had a fever during the period of neutropenia but no patient died of infective complications. There were no deaths from the induction chemotherapy, but one patient died during the second HDM procedure. This patient had grade 4 thrombocytopenia from day 6 following bone marrow return. She had problems with pulmonary infiltration due to infection and intrapulmonary haemorrhage from day 19. Although this improved with antibiotics and platelet support she developed a left hemiparesis and became increasingly unconscious on day 30. She died several hours later. The cause of death was thought to be due to an intracerebral haemorrhage. A postmortem was refused. This was the patient who had received high dose cyclophosphamide prior to her two HDM procedures.
Discussion
The prognosis for patients with myeloma has clearly improved since the introduction of low dose alkylating agents which give a median survival of 24-36 months (Durie & Salmon, 1982; Sporn & McIntyre, 1986 (Gahrton et al., 1991) . We now routinely check the HLA status of the patient prior to the high dose procedure so that HLA matched platelets can be given if no increment occurs with unmatched platelets. The comparable periods of neutropenia probably result from reinfusion of autologous marrow with the higher dose of melphalan on the second occasion.
Of interest is the relatively high complete remission rate (18%) to induction chemotherapy prior to the second HDM procedure. This compares with 6-28% in previously untreated patients using VAMP (Gore et al., 1989) al., 1988) .
Following the entire VAMP HDM or cVAMP HDM a total of 16 patients (55%) achieved a complete remission. This is very simliar to the complete remission rate for previously untreated patients (Gore et al., 1989) . It is noteworthy that this procedure is of value even in patients who do not respond to induction therapy: four patients subsequently achieved a complete remission and eight a partial response. However, this group has been specifically selected because of previous response to high dose chemotherapy and confirms our earlier report of high response rates in previously treated patients using cVAMP (Forgeson et al., 1988) .
Of further interest is the long duration of remission that can occur following the second high dose procedure. This compares favourably with the response duration achieved by responding patients who received VAMP alone (Forgeson et al., 1988) . Patients treated with low dose melphalan before HDM have a universally short remission-free period (Selby et al., 1987) suggesting that a higher dose of melphalan does between first and second high dose melphalan. (McElwain et al., 1989 ) and a-Interferon may have great promise in this context (Mandelli et al., 1990 Until such time as it is possible to cure this disease repeat high dose melphalan remains a useful therapeutic modality to achieve second remissions. We advocate that for fit patients under the age of 65 years bone marrow for cryopreservation is taken following the first HDM procedure. On relapse the patient receives induction chemotherapy followed by HDM (200 mg m-' with the cryopreserved autograft) as part of a planned programme of treatment.
